SCHEDULE: Major Shareholder Reduces Vor Biopharma Stake

Reprogrammed Interchange LLC and Reid Hoffman significantly reduced their beneficial ownership in Vor Biopharma Inc. through open market sales.

Summary

• Reprogrammed Interchange LLC and Reid Hoffman, collectively the Reporting Persons, filed Amendment No. 8 to their Schedule 13D for VOR BIOPHARMA INC.
• The amendment reports open market sales of Vor Biopharma Inc. common stock by Reprogrammed Interchange LLC between October 15, 2025, and October 16, 2025.
• These sales resulted in a decrease of beneficial ownership by more than one percent of the outstanding shares.
• Specifically, 71,655 shares were sold on October 15, 2025, at a weighted average price of $31.9196 per share.
• An additional 2,021 shares were sold on October 16, 2025, at a weighted average price of $30.4548 per share.
• Following these transactions, the Reporting Persons beneficially own 1,204,442 shares, representing 17.6% of the common stock.
• The filing also details numerous other sales by Reprogrammed Interchange LLC during the past 60 days, from August 25, 2025, through October 14, 2025, with prices ranging from $42.3256 to $30.3192.
• A 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock was effected on September 18, 2025, and all share amounts and weighted average sale prices from August 25, 2025, through September 16, 2025, reflect this split.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant and continuous selling activity by a major shareholder, Reprogrammed Interchange LLC, which has reduced its stake by more than one percent. This divestment, especially at declining prices, typically signals a lack of confidence from a key investor and can exert downward pressure on the stock.

Negatives

• A significant shareholder, Reprogrammed Interchange LLC, has reduced its stake in Vor Biopharma Inc. by more than one percent of the outstanding shares.
• The continuous selling activity by a major holder over the past 60 days, including sales at decreasing prices, could signal a lack of confidence or a strategic exit.
• The sales occurred at weighted average prices ranging from $31.9196 to $30.4548 in mid-October, following earlier sales at higher prices, indicating a downward trend in sale prices.

Risks

• Significant reduction in ownership by a major institutional investor could lead to negative market perception and increased selling pressure on the stock.
• The ongoing divestment by a key shareholder may indicate concerns about the company's future prospects or valuation.
• The reverse stock split effected on September 18, 2025, could be a sign of underlying issues, as companies often conduct reverse splits to boost share price and maintain listing requirements, which can sometimes be followed by further price declines.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on past share transactions by the Reporting Persons.

Industry Context

This filing primarily reflects a change in a significant shareholder's position rather than broader industry trends. However, a major investor reducing its stake in a biopharma company could be interpreted by the market as a signal regarding the company's specific prospects within the competitive and capital-intensive biotechnology sector.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential downward pressure on the stock price due to the significant selling by a major investor.
• Potential Investors: May view the divestment as a red flag, potentially deterring new investment.

Key Dates

Recommendation

The continuous and significant selling by a major shareholder, Reprogrammed Interchange LLC, reducing its stake by over one percent and selling at declining prices, indicates a lack of confidence from a sophisticated investor. This sustained divestment, coupled with the recent reverse stock split, suggests potential underlying issues or a strategic exit by a key holder, which could lead to further downward pressure on the stock. Investors should consider selling to mitigate potential losses.

Keywords

VOR BIOPHARMA INC., VBP, Reprogrammed Interchange LLC, Reid Hoffman, Schedule 13D/A, Beneficial Ownership, Share Sales, Insider Selling, Biopharma, Biotechnology, SEC Filing, Stock Split